COVID-19 and Peripheral Neuropathy

The American Academy of Otolaryngology and UK ENT, a professional membership body at The Royal College of Surgeons of England, announced recently on their websites that there is strong anecdotal evidence that the loss of smell is often a symptom of COVID-19 infection.  Another sensory defect that has been observed as a consequence of the infection is loss of taste in some patients.  As this information becomes disseminated, physicians and patients may be concerned if there are any sensory defects in the lower extremities associated with COVID-19?

At present, there is no reason to believe that COVID-19 is responsible for any sensory defects of the lower extremity.  In fact, The Foundation for Peripheral Neuropathy, a reputable patient advocacy group with a highly qualified scientific advisory board, recently sent an email to their members stating that it:


“has looked to its experts and advisors for recommendations for        patients with peripheral neuropathy.  Thankfully, FPN has recently confirmed that there is no known neurological effect from the virus.”


On a personal note, I would like to take this opportunity to wish all of you the best of luck during these trying times.  These are truly dark days, but they will pass.


A request from the author:
Have any of your patients who have taken NeuRemedy experienced any benefits in addition to improvement in their neuropathic symptoms? If so, I would like to know. Please contact me at or call me at 561-549-9099.

Dr. Mann bust-shotDr. Richard H Mann, DABPS, ret
Chief Scientific Officer & Founder, Realm Labs

If you would like to speak with Dr. Mann about how to improve your outcomes in the treatment of polyneuropathy call 866-634-2745 or email Dr. Mann at

Dr. Mann is the developer of the  NeuRemedy®line of benfotiamine nutritional supplements. NeuRemedy is a safe, proven, and effective nutritional formulation dispensed by physicians to their patients suffering from numbness, tingling, burning and/or shooting pains in the feet and legs.  Thiamine (vitamin B1) deficiency often accompanies and intensifies these symptoms. The reversal of thiamine deficiency is an important therapeutic goal in the management of these patients.*

The key ingredient in NeuRemedy, benfotiamine, is the most highly bioactive oral form of thiamine available. It rapidly and safely reverses thiamine deficiency, improving the functioning of the nerves in the feet and legs. Each capsule of NeuRemedy contains 150 mg of benfotiamine in a proprietary formulation. Because of its impressive success rate and high safety profile, NeuRemedy was recently licensed in Canada as an important factor in supporting healthy nerve function in individuals with polyneuropathy.*

NeuRemedy is the leader in the field with thousands of physicians and patients relying each day on its efficacy, purity, safety and rapid onset of action.*

For more information on NeuRemedy:
In the USA contact Realm Labs at 866-634-2745.
In Canada contact OHI at 855-561-4156.

Leave a Reply

Your email address will not be published. Required fields are marked *